Bipolar I disorder (BP-I) is a severe and chronic psychiatric condition characterized by recurrent episodes of mania and depression that significantly impact quality of life and functioning. Early recurrence, high relapse rates, and poor adherence to daily oral medications complicate long-term management and increase the risk of hospitalization and suicide. Long-acting injectable antipsychotics (LAIs) offer a potential solution to these challenges by promoting sustained medication delivery and efficacy, reducing pharmacokinetic variability, and improving treatment adherence. Among available LAIs, aripiprazole is the only partial dopamine D₂ receptor agonist, which may contribute to its favorable tolerability and mood-stabilizing properties. Despite the robust evidence for the efficacy and tolerability of aripiprazole monohydrate LAIs in patients with BP-I, this agent remains underutilized in this population. Misperceptions about efficacy and tolerability, coupled with systemic and prescriber-level barriers, have limited broader clinical adoption. To address these issues, a round table panel of experts in psychopharmacology, the clinical treatment of bipolar disorder, and antipsychotic prescribing was convened to evaluate the clinical rationale for earlier use of aripiprazole monohydrate LAIs in BP-I and to identify key challenges limiting its use. This article summarizes their consensus on the pharmacological distinctiveness, practical advantages, and potential of aripiprazole monohydrate LAIs in improving long-term outcomes in individuals with BP-I.
Goldberg et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: